title: Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor beta-1, soluble fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC Study.
abstract: BACKGROUND
  The prognosis of stomach cancer with advanced stage remains poor. New biomarkers of the disease that may contribute to establish the potential screening strategy would be of value for the early detection of individuals at high risk of the disease.
  
  
  METHODS
  We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the Japan Collaborative Cohort (JACC) Study, to evaluate serum levels of insulin-like growth factor I, II, and binding protein 3 (IFG-I, IGF-II, and IGFBP-3), transforming growth factorbeta-1 (TGFbeta1), soluble fas (sFas) and superoxide dismutase activity (SOD) in 210 stomach cancer cases diagnosed in the JACC Study in relation to those levels in their 410 controls.
  
  
  RESULTS
  Among 6 serum biomarkers tested for case-control differences, only sFas level in female stomach cancer cases was significantly higher than that of controls (2.22 pg/ml vs. 2.04 pg/mL, respectively; P=0.013 by two-way analysis of covariance controlling for matching variable).
  
  
  CONCLUSIONS
  None of the biomarkers consistently predicted future risk of stomach cancer in both men and women in the present analysis. Serum sFas level in women, however, should be studied much more thoroughly whether it provides meaningful refinement of risk stratification, or it elucidate the mechanisms of tumorigenesis in women.
authors.affiliation: Department of Public Health/ Health Information Dynamics, Nagoya University Graduate School of Medicine, Japan. h828@med.nagoya-u.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yatsuya
authors.forename: Hideaki
authors.initials: H
authors.lastname: Toyoshima
authors.forename: Koji
authors.initials: K
authors.lastname: Tamakoshi
authors.forename: Akiko
authors.initials: A
authors.lastname: Tamakoshi
authors.forename: Takaaki
authors.initials: T
authors.lastname: Kondo
authors.forename: Norihiko
authors.initials: N
authors.lastname: Hayakawa
authors.forename: Kiyomi
authors.initials: K
authors.lastname: Sakata
authors.forename: Shogo
authors.initials: S
authors.lastname: Kikuchi
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Hoshiyama
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Fujino
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mizoue
authors.forename: Noritaka
authors.initials: N
authors.lastname: Tokui
authors.forename: Takesumi
authors.initials: T
authors.lastname: Yoshimura
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D007564:Japan; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood*; D016212:Transforming Growth Factor beta / Q000097:blood*; D053773:Transforming Growth Factor beta1
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D018972:Insulin-Like Growth Factor Binding Protein 3; D008562:Membrane Glycoproteins; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013482:Superoxide Dismutase